A Phase 1b/2a clinical trial of bisantrene RC220 in combination with oral decitabine/cedazuridine in dose escalation studies, followed by a triple combination with a standard of care treatment
Latest Information Update: 11 Aug 2023
At a glance
- Drugs Bisantrene (Primary) ; Cedazuridine/decitabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Race Oncology
Most Recent Events
- 11 Aug 2023 New trial record
- 08 Aug 2023 According to Race oncology media release, the company retains a solid cash reserve and this study is fully funded.
- 08 Aug 2023 According to Race oncology media release, the trial is planned to start in late Q4 CY 2023, with transitional phases from RC110 to RC220 in 2024.